Pfizer Announces Termination of Proposed Combination with Allergan

Morgan Stanley Resumes Pfizer (PFE) at Equalweight

Morgan Stanley resumed coverage on Pfizer (NYSE: PFE) with an Equalweight rating and a price target of $35. Its prior rating was Overweight.

For an analyst ratings summary and ratings history on Pfizer click here. For more ratings news on Pfizer click here.

Shares of Pfizer closed at $32.93 yesterday.

JPMorgan Resumes Pfizer (PFE) at Overweight

JPMorgan resumed coverage on Pfizer (NYSE: PFE) with an Overweight rating and a price target of $38.00.

For an analyst ratings summary and ratings history on Pfizer click here. For more ratings news on Pfizer click here.

Shares of Pfizer closed at $32.93 yesterday.

Susquehanna Downgrades Allergen (AGN) to Neutral

Susquehanna downgraded Allergen (NYSE: AGN) from Positive to Neutral.

For an analyst ratings summary and ratings history on Allergen click here. For more ratings news on Allergen click here.

Shares of Allergen closed at $244.74 yesterday.

Allergen's (AGN) Price Target Reduced to $282 at Deutsche Bank

Deutsche Bank maintained a Buy rating on Allergen (NYSE: AGN) but lowered its price target to $282.00 (from $339.00). Earlier its merger with Pfizer (NYSE: PFE) was terminated.

"It is important to note that our estimates and... More

Piper Jaffray Sees Value in Allergen (AGN) Post-Pfizer; PT to $311

Piper Jaffray analyst David Amsellem reiterated his Overweight rating while trimming his price target on Allergen (NYSE: AGN) to $311.00 (from $333.00) after the collapse of the Pfizer deal. The analyst sees ample room for valuation creation post--Pfizer.

"With the collapse of the merger between Allergan... More

BMO Capital Reiterates Outperform on Pfizer (PFE) Following Allergan Merger Termination

BMO Capital reiterated an Outperform rating and $39.00 price target on Pfizer (NYSE: PFE) following the company's announcement the merger agreement with Allergan plc was terminated. BMO believes that Pfizer will likely look for more deals to strengthen its innovative business, and the recent weakness... More

Standalone Allergan (AGN) Could Be Worth $300 - RBC

Allergan (NYSE: AGN) and Pfizer (NYSE: PFE) have officially called off the proposed combination following Monday night's aggressive Treasury rules that seem aimed to derail the deal. The stock is already reflecting deal break and so from here the focus will pivot to two things (i) what is "standalone" AGN worth and (ii) what is the earnings power. RBC analyst, Randall Stanicky, thinks the stock and Street numbers understate both right now.

AGN will hold a conference call at 10AM ET to discuss outlook from here... More

Leerink Partners Cuts Price Target on Allergan (AGN) Following New U.S. Treasury Regulations

Leerink Partners maintained an Outperform rating on Allergen (NYSE: AGN), and cut the price target to $272.00 (from $340.00), following new U.S. Treasury regulations. The Treasury's temporary regulation regarding new tax inversion rules creates a risk to PFE (MP) - AGN closing.

Analyst Jason Gerberry... More

Allergan (AGN) Affirms Termination of Pfizer (PFE) Merger; Affirms Strength as Standalone Company

Allergan plc (NYSE: AGN) announced that its merger agreement with Pfizer (NYSE: PFE) has been terminated by mutual agreement, effective . In connection with the termination of the merger agreement, Pfizer has agreed to pay Allergan $150 million for reimbursement of expenses associated with the transaction.

Allergan reiterated its compelling standalone growth profile and strategy following the announced termination of the combination of the two companies. Allergan is positioned to drive strong, sustainable growth powered by leading franchises, new potential blockbuster product launches and unmatched pipeline.

"While we... More